Drug Patents owned by Phathom

1. List of Voquezna Dual Pak drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(7 years from now)

Do you want to check out VOQUEZNA DUAL PAK patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: 2031-05-04

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET;ORAL

More Information on Dosage

VOQUEZNA DUAL PAK family patents

11

United States

11

Japan

5

Peru

4

Spain

4

China

4

European Union

3

Brazil

3

Canada

3

Argentina

3

New Zealand

3

Korea, Republic of

3

Taiwan

3

Georgia

2

Hong Kong

2

Dominican Republic

2

Malaysia

2

Denmark

2

RS

2

Poland

2

Ukraine

2

Morocco

EA

2

EA

2

Croatia

2

Cyprus

2

Chile

2

Portugal

2

Australia

2

Costa Rica

2

South Africa

2

Slovenia

1

Uruguay

1

Austria

1

Germany

1

Russia

1

Singapore

1

Norway

1

ME

1

Israel

1

Jordan

1

Mexico

1

Ecuador

1

Colombia

1

Tunisia

2. List of Voquezna Triple Pak drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(7 years from now)

Do you want to check out VOQUEZNA TRIPLE PAK patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: 2031-05-04

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET, TABLET;ORAL

More Information on Dosage

VOQUEZNA TRIPLE PAK family patents

11

United States

11

Japan

5

Peru

4

Spain

4

China

4

European Union

3

Brazil

3

Canada

3

Argentina

3

New Zealand

3

Korea, Republic of

3

Taiwan

3

Georgia

2

Hong Kong

2

Dominican Republic

2

Malaysia

2

Denmark

2

RS

2

Poland

2

Ukraine

2

Morocco

EA

2

EA

2

Croatia

2

Cyprus

2

Chile

2

Portugal

2

Australia

2

Costa Rica

2

South Africa

2

Slovenia

1

Uruguay

1

Austria

1

Germany

1

Russia

1

Singapore

1

Norway

1

ME

1

Israel

1

Jordan

1

Mexico

1

Ecuador

1

Colombia

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in